中国临床药理学与治疗学2012，Vol.17Issue(9)：1074-1080,7.
急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略
Antiplatelet strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
贾亮亮 1柯永胜1
作者信息
- 1. 皖南医学院弋矶山医院心内科,芜湖241001,安徽
- 折叠
摘要
Abstract
Acute coronary syndrome (ACS) is a clinical syndrome caused by acute cardiac an-oxemia, including unstable angina (UA) , non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction(STEMI). The main pathogenesis of ACS is platelet activation and thrombin formation associated with plaque rupture , eventually leading to thrombosis. Currently antiplatelet and anticoagulant therapies become the two important part of the antithrombotic treatment of patients with ACS. With the wide application of
percutaneous coronary intervention therapy (PCI) in patients with ACS, preoperative safety and efficacy of antithrombotic drug are increasingly concerned. This article presents an overview on clinical trials evaluating the different aspects of antiplatelet therapy in patients undergoing PCI and discuss the emerging role of these a-gents in the contemporary era of early invasive coronary intervention.关键词
急性冠脉综合征/经皮冠状动脉介入治疗/抗血小板Key words
Acute coronary syndrome/ Percutaneous coronary intervention/Antiplatelet分类
医药卫生引用本文复制引用
贾亮亮,柯永胜..急性冠脉综合征患者接受经皮冠状动脉介入治疗前后抗血小板策略[J].中国临床药理学与治疗学,2012,17(9):1074-1080,7.
